Gallant Closes $18 Million Series B to Bring Ready-to-Use Stem Cell Therapies for Pets to Market

Gallant 完成 1800 万美元 B 轮融资，将推出宠物即用型干细胞疗法

• Gallant raises $18 million in Series B financing, led by Digitalis Ventures, to advance the first ready-to-use stem cell therapy through conditional FDA approval.

• Gallant 在 Digitalis Ventures 领投的 B 轮融资中筹集了 1800 万美元，以推动首个即用型干细胞疗法通过 FDA 的有条件批准。

• NovaQuest joins as a new investor, bringing deep experience from the first human FDA-approved allogeneic stem cell therapy, to support Gallant's leadership in veterinary regenerative medicine.

• NovaQuest作为新投资者加入，带来了从首个获得美国FDA批准的同种异体干细胞疗法中积累的深厚经验，以支持Gallant在兽医再生医学领域的领导地位。

• Continued significant support from BOLD Capital and Hill Creek Partners, further validating Gallant's potential by sophisticated investors and animal health industry insiders.

• BOLD Capital 和 Hill Creek Partners 持续提供重要支持，进一步由资深投资者和动物健康行业内部人士验证了 Gallant 的潜力。

SAN DIEGO, June 30, 2025-- Gallant, an animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, announced the successful closing of its $18 million Series B financing. The round was led by Digitalis Ventures, with continued support from BOLD Capital and Hill Creek Partners, and new participation from NovaQuest Capital Management..

圣地亚哥，2025年6月30日——Gallant是一家致力于为宠物提供现成干细胞疗法的动物健康生物技术公司，宣布成功完成1800万美元的B轮融资。本轮融资由Digitalis Ventures领投，BOLD Capital和Hill Creek Partners持续支持，并获得NovaQuest Capital Management的新参与。

Gallant is creating a new category in veterinary care with ready-to-use stem cell therapies that target the root cause of the most common and underserved diseases in dogs and cats. Its first product for refractory Feline Chronic Gingivostomatitis (FCGS) is on track for FDA conditional approval in early 2026, and could become the first FDA-labeled, allogeneic stem cell therapy in veterinary medicine..

Gallant 正在兽医护理领域开创一个新类别，推出即用型干细胞疗法，针对猫狗最常见的且未被充分治疗的疾病的根源。其首款用于难治性猫慢性龈口炎 (FCGS) 的产品有望在 2026 年初获得 FDA 有条件批准，并可能成为兽医学中首个获得 FDA 标签认证的同种异体干细胞疗法。

With this funding, Gallant accelerates its path to initial commercial rollout of its lead product for FCGS, while advancing a pipeline of therapies for Canine and Feline Osteoarthritis (COA and FOA), Canine Atopic Dermatitis (CAD), and Feline Chronic Kidney Disease (CKD) – conditions where current standards of care manage symptoms rather than address the underlying disease..

通过这笔资金，Gallant 加快了其用于 FCGS 的主导产品的商业化初期推广进程，同时推进了针对犬骨关节炎 (COA 和 FOA)、犬特应性皮炎 (CAD) 以及猫慢性肾病 (CKD) 的一系列治疗方案的开发——这些疾病目前的护理标准是管理症状，而不是解决潜在病因。

'We have been continually impressed by Gallant's team, clarity of vision, and ability to deliver. They're tackling some of the most persistent needs in animal health using their proprietary technology platform to bring truly differentiated solutions to veterinarians and pets in need – meaningful innovation that targets the disease, not just symptoms,' said Dr.

“我们一直对加兰特团队的愿景清晰度和交付能力印象深刻。他们正在利用自己的专有技术平台，解决动物健康领域一些最持久的需求，为兽医和需要帮助的宠物提供真正差异化的解决方案——这种有意义的创新针对的是疾病本身，而不仅仅是症状，”博士说道。

Cindy Cole, Technical Partner at Digitalis Ventures..

辛迪·科尔，Digitalis Ventures技术合伙人。

'Gallant has made significant strides in a short time, advancing a new class of therapies grounded in science and built for scale,' said Teymour Boutros-Ghali, Managing Partner at BOLD Capital. 'As it moves through FDA review toward commercialization, we're excited to stand behind a team pushing the boundaries of what's possible in veterinary care.'.

“Gallant 在短时间内取得了显著的进展，推出了一类基于科学并具备规模化能力的新型疗法，”BOLD Capital 的管理合伙人 Teymour Boutros-Ghali 表示。“随着其通过 FDA 审查并迈向商业化，我们非常高兴能够支持一个在兽医护理领域不断突破可能界限的团队。”

NovaQuest Capital Management's participation brings notable category experience with their investment in Mesoblast. Their first product, RYONCIL®, became the first-ever FDA-approved human allogeneic mesenchymal stromal cell (MSC) therapy in the U.S. in December 2024.

NovaQuest资本管理公司的参与为他们投资的Mesoblast带来了显著的领域经验。其首款产品RYONCIL®于2024年12月成为美国首个获得FDA批准的人类同种异体间充质基质细胞（MSC）疗法。

'Regenerative medicine is entering its prime – we've seen it firsthand with the success of allogeneic stem cell therapies in human healthcare,' said Brian Axe, Partner at NovaQuest. 'Gallant is bringing that same caliber of science to animal health with off-the-shelf therapies for pets targeting the root cause of disease where current care falls short.

“再生医学正进入其黄金时期——我们已经亲眼见证了同种异体干细胞疗法在人类医疗领域的成功，”NovaQuest的合伙人布莱恩·艾克斯表示。“Gallant正在将同等水平的科学应用到动物健康领域，为宠物提供现成的治疗方法，针对当前治疗不足的疾病根源。”

We're thrilled to help bring these pioneering therapies to market.'.

我们很高兴能帮助这些开创性疗法走向市场。

Gallant's research, focused on canine and feline osteoarthritis, feline chronic kidney disease, and feline chronic gingivostomatitis, found that only 56% of veterinarians are satisfied with treatments for canine OA – and just 8% for FCGS. Most veterinarians understand that current therapies manage symptoms, not the underlying disease, and roughly half of veterinarians express a strong interest in using regenerative medicine across conditions.

加兰特的研究聚焦于犬和猫的骨关节炎、猫慢性肾病以及猫慢性齿龈口炎，发现只有56%的兽医对犬骨关节炎的治疗感到满意，而对猫慢性齿龈口炎的治疗感到满意的兽医仅占8%。大多数兽医明白目前的疗法只能缓解症状，而不能解决潜在的疾病，大约一半的兽医表示对在各类病症中使用再生医学有浓厚兴趣。

Gallant's therapies are designed to meet that demand: ready-to-use, science-backed, and developed under FDA oversight..

加兰特的疗法旨在满足这一需求：即用型、科学支持、并在FDA监督下开发。

'We're honored to have the backing of partners who share our vision in creating this new category of medicine that doesn't just help pets feel better, but helps pets get better,' said Dr. Linda Black, CEO of Gallant. 'The FDA approval of the first human allogeneic stem cell therapy was a historic milestone, and we're looking forward to delivering this breakthrough therapy for animal health.'.

“我们很荣幸得到与我们拥有相同愿景的合作伙伴的支持，共同创造这一不仅帮助宠物感觉更好，而且帮助宠物康复的新型医药品类，”Gallant首席执行官琳达·布莱克博士说道。“FDA批准首个同种异体干细胞疗法是历史性的里程碑，我们期待为动物健康带来这一突破性疗法。”

Gallant's proprietary stem cell platform harnesses the unique potential of uterine-derived mesenchymal stem cells. The anticipated conditional approval of the FCGS therapy would offer new hope to cats facing this debilitating disease and help lay the regulatory roadmap for future off-the-shelf stem cell therapies.

Gallant的专有干细胞平台利用了子宫源间充质干细胞的独特潜力。预计FCGS疗法的有条件批准将为面临这种衰弱疾病的猫带来新的希望，并有助于为未来现成的干细胞疗法奠定监管路线图。

This work is part of Gallant's larger mission: to make stem cell therapy accessible to every pet who needs it..

这项工作是Gallant更大使命的一部分：让每个需要干细胞治疗的宠物都能获得这种疗法。

About Gallant

关于加兰特

Gallant is an animal health biotechnology company creating a new category of veterinary medicine with a pipeline of off-the-shelf stem cell therapies targeting the root causes of diseases in pets. Led by pioneers in veterinary regenerative medicine with deep expertise in development, manufacturing, and commercialization, Gallant is making regenerative medicine accessible – moving beyond symptom management to restoring health at the source.

Gallant是一家动物健康生物技术公司，致力于通过一系列现成的干细胞疗法创建一个全新的兽医药品类别，针对宠物疾病的根本原因进行治疗。由兽医再生医学领域的先驱领导，团队在研发、制造和商业化方面拥有深厚的专业知识，Gallant正在使再生医学变得触手可及——超越症状管理，从源头恢复健康。

Learn more at https://www.gallant.com/..

更多信息请访问 https://www.gallant.com/..

About Digitalis Ventures

关于Digitalis Ventures

Digitalis Ventures backs founders solving critical problems in health. The firm invests in early-stage companies across the healthcare ecosystem with the goal of supporting them through multiple rounds of financing. Digitalis is headquartered in New York City. Learn more at https://www.digitalisventures.com/..

Digitalis Ventures支持解决健康领域关键问题的创始人。该公司投资于医疗保健生态系统中的早期公司，目标是通过多轮融资支持它们。Digitalis总部位于纽约市。更多信息请访问https://www.digitalisventures.com/。

About BOLD Capital

关于BOLD资本

BOLD Capital is a venture capital firm focused on partnering with entrepreneurs and companies that share a bold vision for a brighter future. The firm invests primarily in two transformative areas: health and life sciences, and deep tech and productivity. BOLD identifies emerging science and technologies with the potential to disrupt and democratize massive markets, creating innovative solutions to some of humanity's most pressing challenges.

BOLD Capital 是一家风险投资公司，致力于与那些对未来充满大胆愿景的企业家和公司合作。该公司主要投资于两大变革性领域：健康与生命科学，以及深度科技与生产力。BOLD 识别具有颠覆性和民主化巨大市场潜力的新兴科学和技术，为人类一些最紧迫的挑战创造创新解决方案。

The firm is headquartered in Santa Monica, California. Learn more at https://boldcapitalpartners.com/..

公司总部位于加利福尼亚州圣莫尼卡。更多信息请访问 https://boldcapitalpartners.com/。

About NovaQuest Capital Management

关于NovaQuest资本管理公司

NovaQuest Capital Management, located in North Carolina's Research Triangle, is a life science investment firm with a specialization in biopharmaceuticals. Founded in 2010, and with more than $2.5 billion raised across multiple funds, NovaQuest provides tailored capital solutions that fund innovation in biopharmaceutical development and invests in compelling healthcare companies with products and technologies aimed at helping humans and animals live healthier, longer, more productive lives.

位于北卡罗来纳州研究三角区的NovaQuest Capital Management是一家专注于生物制药的生命科学投资公司。该公司成立于2010年，已通过多个基金筹集了超过25亿美元的资金。NovaQuest提供定制的资本解决方案，为生物制药开发中的创新提供资金，并投资于拥有引人注目的医疗保健公司，这些公司致力于开发帮助人类和动物更健康、更长寿、更高产生活的产品和技术。

Learn more at https://www.novaquest.com/..

了解更多，请访问 https://www.novaquest.com/..

Contact:

联系：

Galyna Danylenko

加琳娜·达尼连科

+1 (443) 254-7567

+1 (443) 254-7567

397379@email4pr.com

397379@email4pr.com